Is hypercoagulation a predictor influencing the efficiency of immunotherapy for metastatic renal cancer?
https://doi.org/10.17650/1726-9776-2007-3-1-30-32
Abstract
In experimental systems, interference with coagulation can affect tumor biology. Tumor-mediated activation of the hemostatic system has been implicated in both the formation of tumor stroma and the promotion of hematogenous metastasis. We emphasize that hypercoagulation is a frequent symptom in metastatic renal cell carcinoma (MRCC) patients and clinically correlates with progression of the disease. It has been suggested that hypercoagulation is a possible negative predictor for a response to immunotherapy in MRCC patients.
About the Authors
I. V. Timofeyev
N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences I.M. Sechenov Moscow Medical Academy
Russian Federation
Russian Federation
A. V. Madzhuga
N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences I.M. Sechenov Moscow Medical Academy
Russian Federation
Russian Federation
L. V. Demidov
N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences I.M. Sechenov Moscow Medical Academy
Russian Federation
Russian Federation
O. V. Somonova
N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences I.M. Sechenov Moscow Medical Academy
Russian Federation
Russian Federation
G. Yu. Kharkevich
N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences I.M. Sechenov Moscow Medical Academy
Russian Federation
Russian Federation
A. L. Yelizarova
N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences I.M. Sechenov Moscow Medical Academy
Russian Federation
Russian Federation
References
1. Kakkar A.K., Williamson R.C. Antithrombotic therapy in cancer. BMJ 1999; 318(7198): 1571—2.
2. Kakkar A.K., DeRuvo N., Chinswangwatanakul V. et al. Extrinsicpathway activation in cancer with high factor VIIa and tissue factor. Lancet 1995;346(8981):1004—5.
3. Kharkevich G., Tsimafeyeu I., Demidov L. Low-dose IL-2 in combination with IFN and 5-FU for metastatic renal cell carcinoma. J Eur Urol 2006;5(2 Suppl):286.
4. Misbah S.A., Shaheen P.E., Elson P.J. et al. Thrombocytosis as a prognostic factor for survival in patients with metastatic renal cell carcinoma. JCO 2005;23:4599.
5. Sampson M.T., Kakkar A.K. Coagulation proteases and human cancer. Biochem Soc Trans 2002;30(2): 201—7.
Review
For citations:
Timofeyev I.V., Madzhuga A.V., Demidov L.V., Somonova O.V., Kharkevich G.Yu., Yelizarova A.L. Is hypercoagulation a predictor influencing the efficiency of immunotherapy for metastatic renal cancer? Cancer Urology. 2007;3(1):30-32. (In Russ.) https://doi.org/10.17650/1726-9776-2007-3-1-30-32
Views:
371
Email this article 